Literature DB >> 19537829

Increased confidence in large-scale phosphoproteomics data by complementary mass spectrometric techniques and matching of phosphopeptide data sets.

Maria P Alcolea1, Oliver Kleiner, Pedro R Cutillas.   

Abstract

Large-scale phosphoproteomics studies are of great interest due to their potential for the dissection of signaling pathways controlled by protein kinases. Recent advances in mass spectrometry (MS)-based phosphoproteomic techniques offer new opportunities to profile protein kinase activities in a comprehensive manner. However, this increasingly used approach still poses many analytical challenges. On one hand, high stringency criteria for phosphopeptide identification based on MS/MS data are needed in order to avoid false positives; however, on the other hand, these stringent criteria also result in the introduction of many false negatives. In the current report, we employ different mass spectrometric techniques for large-scale phosphoproteomics in order to reduce the presence of false negatives and enhance data confidence. A LTQ-Orbitrap LC-MS/MS platform identified approximately 3 times more phosphopeptides than Q-TOF LC-MS/MS instrumentation (4308 versus 1485 identifications, respectively). In both cases, collision induced dissociation (CID) was used to fragment peptides. Interestingly, the two platforms produced complementary data as many of the low scoring phosphopeptide ions identified by LTQ-Orbitrap MS/MS gave rise to high score identifications by Q-TOF MS/MS analysis, and vice versa. In fact, approximately 450 phosphopeptides identified by the Q-TOF instrument were not identified by the LTQ-Orbitrap. Further data comparison revealed the extent of the problem: in one experiment, the estimated number of false negatives (1066) was close to the number of identified phosphopeptides (1485). This work demonstrates that by using standard procedures for phosphopeptide identification the number of false negatives can be even greater than the number of false positives. We propose using historical phosphoproteomic data and spectral matching algorithms in order to efficiently minimize false negative rates.

Mesh:

Substances:

Year:  2009        PMID: 19537829     DOI: 10.1021/pr800955n

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  8 in total

1.  A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments.

Authors:  Pedro Casado; Pedro R Cutillas
Journal:  Mol Cell Proteomics       Date:  2010-10-24       Impact factor: 5.911

Review 2.  Plasma membrane proteomics and its application in clinical cancer biomarker discovery.

Authors:  Rikke Leth-Larsen; Rikke R Lund; Henrik J Ditzel
Journal:  Mol Cell Proteomics       Date:  2010-04-08       Impact factor: 5.911

Review 3.  A survey of computational methods and error rate estimation procedures for peptide and protein identification in shotgun proteomics.

Authors:  Alexey I Nesvizhskii
Journal:  J Proteomics       Date:  2010-09-08       Impact factor: 4.044

4.  Quantitative measurement of phosphoproteome response to osmotic stress in arabidopsis based on Library-Assisted eXtracted Ion Chromatogram (LAXIC).

Authors:  Liang Xue; Pengcheng Wang; Lianshui Wang; Emily Renzi; Predrag Radivojac; Haixu Tang; Randy Arnold; Jian-Kang Zhu; W Andy Tao
Journal:  Mol Cell Proteomics       Date:  2013-05-08       Impact factor: 5.911

5.  Phosphoproteomic profiling of in vivo signaling in liver by the mammalian target of rapamycin complex 1 (mTORC1).

Authors:  Gokhan Demirkan; Kebing Yu; Joan M Boylan; Arthur R Salomon; Philip A Gruppuso
Journal:  PLoS One       Date:  2011-06-28       Impact factor: 3.240

6.  Characterization of a TiO₂ enrichment method for label-free quantitative phosphoproteomics.

Authors:  Alex Montoya; Luisa Beltran; Pedro Casado; Juan-Carlos Rodríguez-Prados; Pedro R Cutillas
Journal:  Methods       Date:  2011-02-18       Impact factor: 3.608

7.  Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors.

Authors:  Pedro Casado; Maria P Alcolea; Francesco Iorio; Juan-Carlos Rodríguez-Prados; Bart Vanhaesebroeck; Julio Saez-Rodriguez; Simon Joel; Pedro R Cutillas
Journal:  Genome Biol       Date:  2013-04-29       Impact factor: 13.583

8.  Host-directed kinase inhibitors act as novel therapies against intracellular Staphylococcus aureus.

Authors:  Natalia Bravo-Santano; Helen Stölting; Frederic Cooper; Narina Bileckaja; Andrea Majstorovic; Nadine Ihle; Luis M Mateos; Yolanda Calle; Volker Behrends; Michal Letek
Journal:  Sci Rep       Date:  2019-03-19       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.